Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aducanumab Seen As Potential AD 'Time Bomb' For Health Budgets

Executive Summary

Alzheimer's disease is a common and growing global menace that threatens health care budgets, but if a cure was ever found demand for the remedy it would likely swamp payer resources.

You may also be interested in...



Biogen CMO Notes iPhone's Potential For Early Detection of Alzheimer's

Biogen's chief medical officer says iPhone technology should in future be used for early warning diagnosis of Alzheimer's Disease.

Biogen Senses 'Interesting Opportunities' If Financial Markets Remain Challenging

Biogen Inc. has earmarked $100m for business development in 2016, an investment the company hopes to take advantage of if the financial markets continue to be challenging for young biotechs, driving down valuations for assets.

Mixed bag? Biogen's aducanumab shows continued dose-correlation

Biogen reported data from the 6mg/kg cohort of its PRIME trial of aducanumab at the Alzheimer's Association International Conference (AAIC) on 22 July that will likely leave investors itching for more clarity. The data continue to show dose correlation in efficacy, but safety issues persist at the mid-range dose as well.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS120356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel